Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
Open Access
- 1 September 1989
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 170 (3) , 1015-1020
- https://doi.org/10.1084/jem.170.3.1015
Abstract
Passive immunization against TNF allowed non-tumor-bearing C3H/HEN mice and tumor-bearing C57BL/6 mice to tolerate significantly more doses of IL-2 before death (p < 0.005 and p < 0.001, respectively). The antitumor effect of IL-2 against both 3-d and 10-d pulmonary metastases was maintained in mice treated concurrently with neutralizing antibodies to TNF. In one experiment with 10-d pulmonary metastases increased administration of IL-2 made possible by passive immunization against TNF significantly improved the antitumor response compared to equitoxic doses of IL-2 and control antibody. The results indicate that TNF is a mediator of IL-2 toxicity but contributes minimally to the antitumor effects of IL-2. Strategies to inhibit TNF may improve the therapeutic index of IL-2 as a neoplastic agent.Keywords
This publication has 16 references indexed in Scilit:
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- The Hemodynamic Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJournal of Clinical Immunology, 1988
- CIRCULATING CYTOKINES IN PATIENTS WITH METASTATIC CANCER TREATED WITH RECOMBINANT INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS1988
- Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced CancerAnnals of Internal Medicine, 1987
- Shock and Tissue Injury Induced by Recombinant Human CachectinScience, 1986
- Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.The Journal of Immunology, 1986
- In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.The Journal of Immunology, 1985
- Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.The Journal of Immunology, 1985
- Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of EndotoxinScience, 1985